Highnoon Laboratories Limited (PSX: HINOON)

Market Cap	36.87B
Revenue (ttm)	21.89B
Net Income (ttm)	2.84B
Shares Out	52.98M
EPS (ttm)	53.61
PE Ratio	12.98
Forward PE	n/a
Dividend	30.00 (4.31%)
Ex-Dividend Date	Apr 18, 2024

Volume	5,310
Open	705.00
Previous Close	698.82
Day's Range	693.50 - 710.00
52-Week Range	330.00 - 840.93
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Highnoon Laboratories

Highnoon Laboratories Limited, together with its subsidiaries, manufactures, imports, sells, exports, and markets pharmaceutical and allied consumer products. It offers products in various therapeutic areas, including allergy, anti-infective, cardiology, gastroenterology, metabolic, musculoskeletal, obstetrics and gynaecology, paediatrics, respiratory, and urology; and generic products under various brands. The company serves Pakistan, Afghanistan, the United Arab Emirates, France, Kenya, Iraq, Cambodia, Tanzania, and internationally. Highnoon ...

• Industry: Pharmaceuticals
• Sector: Healthcare
• Founded: 1984
• Employees: 2,295
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: HINOON

Financial Performance

In 2023, Highnoon Laboratories's revenue was 19.77 billion, an increase of 24.98% compared to the previous year's 15.82 billion. Earnings were 2.45 billion, a decrease of -1.01%.